Max Jan is a physician-scientist principal investigator at Massachusetts General Hospital. His research group is focused on developing clinically suitable synthetic biology systems and with them precision, tunable cellular immunotherapies. As a molecular pathologist, he applies genomic technologies to support precision medicine for people with cancer. Dr. Jan attended college at Princeton, received a PhD in Cancer Biology from Stanford, and completed medical school at UCSF. He was a resident and fellow at Mass General before starting his lab in 2021. He is an Assistant Professor of Pathology at Harvard Medical School and a member of the MGH Cellular Immunotherapy Program.

David Raulet is the Esther and Wendy Schekman Chair in Cancer Biology and a Distinguished Professor of Immunology and Molecular Medicine in the Department of Molecular and Cell Biology at UC Berkeley. He is also Director of the Immunotherapeutics and Vaccine Research Initiative at UC Berkeley. He was previously Department Chair and before that Head of the Division of Immunology and Molecular Medicine within the Department. Dr. Raulet received his PhD in Biology from MIT and was a postdoctoral fellow at the University of Pennsylvania School of Medicine, before joining the faculty of the Biology Department at MIT in 1983 as an Assistant Professor. He moved to the Department of Molecular and Cell Biology at UC Berkeley in 1991. He is a member of the National Academy of Sciences and is also a co-founder of Dragonfly Therapeutics.